Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoko Shimada

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Thoracic Cancer|March 25, 2021
Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinibFariz Nurwidya, Fumiyuki Takahashi, Wira Winardi, et al.
Respiratory Investigation|August 8, 2024
Clinical potential of SKP2 as diagnostic marker and therapeutic target in small cell lung cancerNaohisa Matsumoto, Ken Tajima, Fumiyuki Takahashi, et al.
JTO Clinical and Research Reports|May 30, 2023
A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With <i>ALK</i>-Positive NSCLC in JapanYasushi Goto, Hirotsugu Kenmotsu, Motohiro Tamiya, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Thoracic Cancer|March 25, 2021
Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinibFariz Nurwidya, Fumiyuki Takahashi, Wira Winardi, et al.
Respiratory Investigation|August 8, 2024
Clinical potential of SKP2 as diagnostic marker and therapeutic target in small cell lung cancerNaohisa Matsumoto, Ken Tajima, Fumiyuki Takahashi, et al.
JTO Clinical and Research Reports|May 30, 2023
A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With <i>ALK</i>-Positive NSCLC in JapanYasushi Goto, Hirotsugu Kenmotsu, Motohiro Tamiya, et al.
Pageof 6